Individualized treatment for alcohol withdrawal : a randomized double-blind controlled trial

Objective. —To assess the effect of an individualized treatment regimen on the intensity and duration of medication treatment for alcohol withdrawal. Design. —A randomized double-blind, controlled trial. Setting. —An inpatient detoxification unit in a Veterans Affairs medical center. Patients. —One hundred one patients admitted for the treatment of alcohol withdrawal who could give informed consent and had no history of seizures or medication use that might alter the clinical course of withdrawal. Intervention. —Patients were randomized to either a standard course of chlordiazepoxide four times daily with additional medication as needed (fixed-schedule therapy) or to a treatment regimen that provided chlordiazepoxide only in response to the development of the signs and symptoms of alcohol withdrawal (symptomtriggered therapy). The need for administration of "as-needed" medication was determined using a validated measure of the severity of alcohol withdrawal. Main Outcome Measures. —Duration of medication treatment and total chlordiazepoxide administered. Results. —The median duration of treatment in the symptom-triggered group was 9 hours compared with 68 hours in the fixed-schedule group ( P P Conclusions. —Symptom-triggered therapy individualizes treatment, decreases both treatment duration and the amount of benzodiazepine used, and is as efficacious as standard fixed-schedule therapy for alcohol withdrawal. ( JAMA . 1994;272:519-523)

[1]  R D ADAMS,et al.  The effect of alcohol on the nervous system. , 1953, Research publications - Association for Research in Nervous and Mental Disease.

[2]  C. Klett,et al.  Treatment of the Acute Alcohol Withdrawal State: A Comparison of Four Drugs , 1995, Alcohol health and research world.

[3]  M L Selzer,et al.  A self-administered Short Michigan Alcoholism Screening Test (SMAST). , 1975, Journal of studies on alcohol.

[4]  C. Whitfield,et al.  Detoxification of 1,024 alcoholic patients without psychoactive drugs. , 1978, JAMA.

[5]  J. M. Shaw,et al.  Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. , 1981, Journal of clinical psychopharmacology.

[6]  J. Stinnett,et al.  A Quantitative Inventory of Alcohol Disorders (QIAD): a severity scale for alcohol abuse. , 1982, The American journal of drug and alcohol abuse.

[7]  D. Greenblatt,et al.  Current Status of Benzodiazepines , 1983 .

[8]  C. Naranjo,et al.  Nonpharmacologic intervention in acute alcohol withdrawal , 1983, Clinical pharmacology and therapeutics.

[9]  Lee Goldman,et al.  Cecil Textbook of Medicine , 1985 .

[10]  G. Baumgartner,et al.  Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. , 1987, Archives of internal medicine.

[11]  A. Foy,et al.  Use of an objective clinical scale in the assessment and management of alcohol withdrawal in a large general hospital. , 1988, Alcoholism, clinical and experimental research.

[12]  J. Ballenger,et al.  Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. , 1989, The American journal of psychiatry.

[13]  C. Naranjo,et al.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). , 1989, British journal of addiction.

[14]  P. Monti,et al.  Detoxification of alcoholics: improving care by symptom-triggered sedation. , 1990, Alcoholism, clinical and experimental research.

[15]  E. Sellers,et al.  Characterization of DSM-III-R criteria for uncomplicated alcohol withdrawal provides an empirical basis for DSM-IV. , 1991, Archives of general psychiatry.

[16]  G. Baumgartner,et al.  Transdermal Clonidine Versus Chlordiazepoxide in Alcohol Withdrawal: A Randomized, Controlled Clinical Trial , 1991, Southern medical journal.

[17]  J. T. Sullivan,et al.  Benzodiazepine requirements during alcohol withdrawal syndrome: clinical implications of using a standardized withdrawal scale. , 1991, Journal of clinical psychopharmacology.